#United States #Pain Management #Thousand Oaks #Latigo Biotherapeutics #Nav1.8 Inhibitor

Latigo Biotherapeutics Secures Significant Funding for Non-Opioid Pain Relief

Latigo Biotherapeutics, a cutting-edge biotechnology firm focused on revolutionizing pain management, has announced the closing of a substantial $150 million in Series B financing. This funding milestone, propelled by investments from an array of prominent firms including Blue Owl Capital, marks a key advancement in the company’s mission to develop innovative non-opioid therapies that effectively target pain directly at its source.

The Series B financing not only aims to bolster Latigo's clinical programs focusing on highly selective Nav1.8 inhibitors but also expands the company's overall therapeutic pipeline. This is particularly significant in today’s climate, where the demand for alternative pain management solutions, devoid of the addiction risks associated with opioids, has surged.

CEO Nima Farzan emphasized the pressing need for safer pain treatments, stating, "The urgency for non-opioid pain solutions has never been greater. This financing allows us to accelerate the development of our promising portfolio of medications that could transform pain treatment.“ The involvement of existing investors such as Westlake Village BioPartners and Foresite Capital, alongside new backers like Qatar Investment Authority and Cormorant Asset Management, underscores a collective commitment towards advancing the fight against pain without relying on addictive substances.

A notable addition to Latigo’s leadership team is Kevin Raidy, Senior Managing Director at Blue Owl Capital, who has joined the board of directors. Raidy acknowledged the long-standing necessity for innovation in pain management. He remarked, "Latigo stands poised to introduce novel non-addictive treatments that could genuinely impact patients' lives."

Latigo has already begun making strides in its clinical programs, with positive Phase 1 results for its lead candidate, LTG-001. This oral Nav1.8 inhibitor is designed specifically for acute pain management, and initial trial results indicate it is well tolerated, with rapid absorption properties that are crucial for efficacy in pain relief. The encouraging data points towards LTG-001 as a potential best-in-class option in non-opioid therapies.

Furthermore, the company is also advancing LTG-305, another oral selective Nav1.8 inhibitor, which is currently undergoing Phase 1 trials aimed at chronic pain treatment. This trial’s design includes evaluations focusing on safety and tolerability among healthy participants, with hopes of moving towards effective solutions for long-term pain management.

Latigo Biotherapeutics is on a mission to deliver rapid-acting and effective non-opioid medications, revolutionizing a field long dependent on opioid solutions. As the medical community and society at large continue to confront the opioid crisis, the urgency for innovative approaches to pain relief becomes all the more critical. The additional funding and strategic direction provided by new board members are anticipated to play vital roles in accelerating Latigo's journey towards reshaping pain management practices.

For more details on Latigo Biotherapeutics and its innovative clinical programs, visit Latigo's official website. The company's dedication to pioneering non-opioid solutions reflects a significant step forward in creating safer, more effective treatment pathways for those in pain.